Cargando…

Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study

PURPOSE: To compare short-term efficacy and safety of intravitreal brolucizumab injection with aflibercept in treatment-naive neovascular age-related macular degeneration (nAMD) patients. METHODS: A total of 59 eyes from 59 treatment-naive nAMD patients in three hospitals were retrospectively review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Juno, Lee, Sung Jin, Park, Tae Kwann, Sun, Hae Jung, Kim, Hoon Dong, Cho, In Hwan, Han, Jung Woo, Choi, Kyung Seek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Ophthalmological Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587452/ https://www.ncbi.nlm.nih.gov/pubmed/37562440 http://dx.doi.org/10.3341/kjo.2023.0009

Ejemplares similares

Brolucizumab for macular degeneration
Publicado: (2020)

Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration
por: Mukai, Ryo, et al.
Publicado: (2021)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration
por: Park, Joo Youn, et al.
Publicado: (2011)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
por: Barchichat, Ilan, et al.
Publicado: (2022)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients
por: Gesualdo, Carlo, et al.
Publicado: (2023)

Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
por: Ueji, Natsuki, et al.
Publicado: (2023)

Short-term effect of intravitreal brolucizumab injections in patients with neovascular age-related macular degeneration on retinal nerve fiber layer thickness
por: Jun, Sung Yeon, et al.
Publicado: (2023)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration
por: Rispoli, Marco, et al.
Publicado: (2021)

Effect of Intravitreal Brolucizumab in the Treatment of Polypoidal Choroidal Vasculopathy With Foveal Lipid Exudation
por: Carta, Valentina, et al.
Publicado: (2023)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
por: Gigon, Anthony, et al.
Publicado: (2022)

Three-Month Results of Brolucizumab Intravitreal Therapy in Patients with Wet Age-Related Macular Degeneration
por: Michalska-Małecka, Katarzyna, et al.
Publicado: (2021)

Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Kato, Nobuhiro, et al.
Publicado: (2023)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2021)

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
por: Davis, R Prince, et al.
Publicado: (2010)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2022)

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Angermann, Reinhard, et al.
Publicado: (2022)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Shaikh, Saad, et al.
Publicado: (2007)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Retinal pigment epithelial tear after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Singh, Sunil Kumar, et al.
Publicado: (2014)

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
por: Sim, Ha Eun, et al.
Publicado: (2022)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
por: Avaylon, Jaycob, et al.
Publicado: (2020)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2022)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Retinal pigment epithelial tear following intravitreal injection of brolucizumab
por: Ashkenazy, Noy, et al.
Publicado: (2021)

Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection
por: Ueta, Yoshiki, et al.
Publicado: (2023)

Use of nepafenac (Nevanac(®)) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
por: Chen, Eric, et al.
Publicado: (2010)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone
por: Ruiz-Moreno, José Mª, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_moembd4crcditritpuhjq4ha57